Figure 1: On baseline positron emission tomography–computed tomography (a-d), the maximum intensity projection positron emission tomography image (a) shows focal areas of increased¹⁸F-fluorodeoxyglucose uptake in the lower half of the left leg (arrow) and the left inguinal region (broken arrow). No other abnormal¹⁸F-fluorodeoxyglucose uptake is seen in the rest of the body. Transaxial (b) and coronal (c) positron emission tomography–computed tomography images of the left leg demonstrate¹⁸F-fluorodeoxyglucose avid, ulceroproliferative circumferential cutaneous thickening (arrows) without any definite involvement of underlying muscles and bones. Transaxial positron emission tomography–computed tomography images (d) also show left inguinal¹⁸F-fluorodeoxyglucose-avid lymphadenopathy (broken arrow). The follow-up positron emission tomography–computed tomography done after 8 months (e-h) shows similar findings, but the reduction in¹⁸F-fluorodeoxyglucose avidity of both cutaneous lesion (f-g, arrows) and left inguinal node (h, broken arrow)